What is Uri Yablonka’s BCLI share ownership after this Form 4 grant?

After the RSU grant, Uri Yablonka directly holds 218,464 shares of BrainStorm Cell Therapeutics common stock. This figure includes the newly granted restricted stock units as reported in the Form 4 filing.

BrainStorm Cell (BCLI) EVP Uri Yablonka awarded 150,000 RSUs in new grant

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Yablonka Uri reported acquisition or exercise transactions in this Form 4 filing.

BrainStorm Cell Therapeutics executive Uri Yablonka received a grant of 150,000 shares of common stock in the form of restricted stock units. According to the award terms, 50% of the RSUs vest on the grant date and the remaining 50% vest six months later, contingent on continued employment. Following this compensation grant, Yablonka holds 218,464 shares directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Yablonka Uri

Role EVP & Chief Business Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	150,000	$0.00	--

Holdings After Transaction: Common Stock — 218,464 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

RSUs granted: 150,000 shares Grant price: $0.0000 per share Shares owned after grant: 218,464 shares +2 more

5 metrics

RSUs granted 150,000 shares Restricted stock units awarded to EVP & Chief Business Officer

Grant price $0.0000 per share Reported transaction price for RSU award

Shares owned after grant 218,464 shares Total direct holdings following RSU award

Immediate vesting portion 50% of 150,000 RSUs Vests on grant date, subject to award terms

Six-month vesting portion 50% of 150,000 RSUs Vests six months after grant, contingent on employment

Key Terms

restricted stock units, RSUs, vest, Plan, +1 more

5 terms

restricted stock units financial

"Represents shares of restricted stock units ("RSUs") awarded under the Plan."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

RSUs financial

"The RSUs shall vest as to (i) 50% of the award on the date of grant"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

vest financial

"The RSUs shall vest as to (i) 50% of the award on the date of grant"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

Plan financial

"Represents shares of restricted stock units ("RSUs") awarded under the Plan."

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

05/29/2026 - 05:02 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Yablonka Uri

(Last)

(First)

(Middle)

C/O BRAINSTORM CELL THERAPEUTICS INC.

1325 AVENUE OF THE AMERICAS 28TH FLOOR

(Street)

NEW YORK

10019

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BRAINSTORM CELL THERAPEUTICS INC. [ BCLI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP & Chief Business Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/26/2026		A		150,000⁽¹⁾	A	$0.00	218,464	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents shares of restricted stock units ("RSUs") awarded under the Plan. The RSUs shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date.

	/s/ Uri Yablonka	05/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did BCLI executive Uri Yablonka report?

Uri Yablonka reported receiving 150,000 restricted stock units as equity compensation. The award was granted at no cash cost per share and increases his direct holdings to 218,464 shares after the transaction.

How do the 150,000 RSUs granted to BCLI’s Uri Yablonka vest?

The 150,000 RSUs vest in two equal tranches. Half of the award vests on the grant date, while the remaining half vests on the six-month anniversary, conditioned on Yablonka remaining employed through each vesting date.

Was the BCLI RSU grant to Uri Yablonka an open-market purchase?

No, the transaction was classified as a grant or award acquisition, not an open-market purchase. The RSUs were awarded under the company plan at a reported price of $0.0000 per share as part of compensation.

What role does Uri Yablonka hold at BrainStorm Cell Therapeutics (BCLI)?

Uri Yablonka serves as a director and as EVP & Chief Business Officer at BrainStorm Cell Therapeutics. The reported RSU grant reflects equity compensation tied to his executive and board responsibilities at the company.